SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024GlobeNewsWire • 04/18/24
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNGlobeNewsWire • 03/04/24
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsGlobeNewsWire • 02/29/24
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesGlobeNewsWire • 02/27/24
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/24
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/21/23
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/08/23
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 12/05/23
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/29/23
SpringWorks Therapeutics Shares Skyrocket on FDA Approval of Desmoid Tumor DrugInvestopedia • 11/28/23
SpringWorks Therapeutics' stock jumps after FDA approves first treatment for rare type of aggressive tumorsMarket Watch • 11/28/23
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid TumorsGlobeNewsWire • 11/27/23
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study DataZacks Investment Research • 11/17/23
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PNGlobeNewsWire • 11/16/23
SpringWorks Therapeutics: How A Likely FDA Approval Can Kickstart The Stock's Repricing PotentialSeeking Alpha • 11/14/23
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/02/23